|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on June 28, 2002; DOI 10.1182/blood-2002-02-0415.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Molecular Medicine, Beth Israel
Deaconess Medical Center, Boston, MA.
Thrombin signaling in endothelial cells provides an important link
between coagulation and inflammation. We report here that thrombin
induces endogenous Egr-1 mRNA and Egr-1 promoter activity in primary human endothelial cells by approximately 6-fold and 3-fold,
respectively. In transient transfection assays, deletion of the 3'
cluster of serum response elements (SREs), but not the 5' cluster of
SREs, resulted in a loss of thrombin response. When coupled to a
heterologous core promoter, a region spanning the 3' SRE cluster
contained information for thrombin response, whereas a region spanning
the 5' SRE cluster had no such effect. A point mutation of the most
proximal SRE (SRE-1), but not of the proximal Ets motif or upstream
SREs, abrogated the response to thrombin. In electrophoretic mobility
shift assays, nuclear extracts from thrombin-treated cells displayed
increased binding of total and phosphorylated serum response factor
(SRF) to SRE-1. Thrombin-mediated induction of Egr-1 was blocked by
inhibitors of MEK1/2, but not by inhibitors of protein kinase C,
phosphatidylinositol 3-kinase, or p38 mitogen-activated protein kinase
(MAPK). Taken together, these data suggest that thrombin induces Egr-1
expression in endothelial cells by a MAPK-dependent mechanism that
involves an interaction between SRF and SRE-1.
(Blood. 2002;100:4454-4461) Thrombin, a multifunctional serine protease derived
from the zymogen prothrombin, is a key component of the coagulation
cascade, serving to catalyze the conversion of fibrinogen to fibrin. In addition, thrombin plays a role in inflammation by activating a variety
of cell types, including endothelial cells, smooth muscle cells, and
leukocytes. Most of these cellular effects are mediated by
protease-activated receptor-1 (PAR-1), a G-protein coupled receptor.
Thrombin cleaves the receptor, unmasking a tethered ligand, which is
then free to activate the receptor.1,2
Thrombin signaling in endothelial cells results in the early release of
P-selectin,3 prostacyclin, and platelet-activating factor,4 and in the induction of multiple genes, including PAR-1,5 Flk-1/KDR, and Flt-1,6
platelet-derived growth factor (PDGF),7 decay-accelerating
factor,8 endothelin-1,9
interleukin-8,10 monocyte chemotactic
protein,11 E-selectin,7,10 vascular cell
adhesion molecule-1 (VCAM-1),12 and intercellular adhesion molecule-1 (ICAM-1).12,13 Thrombin activation of
endothelial cells results in increased permeability,14,15
proliferation,16 angiogenesis,6 and
leukocyte-endothelial cell interactions.7,12,17
Egr-1 (also known as zif268, TIS 8, NFGI-A, and Krox 24) is a member of
the immediate-early gene family that includes c-fos, c-jun, and early
growth response genes.18-23 Egr-1, which
encodes a serum-inducible zinc finger nuclear phosphoprotein, is
rapidly induced in cultured cells by a wide variety of mitogenic and
nonmitogenic stimuli. In endothelial cells, Egr-1 has been shown to be
activated by acidic fibroblast growth factor,24 basic
fibroblast growth factor,25,26 vascular endothelial growth
factor (VEGF),27 epidermal growth factor
(EGF),28,29 shear stress,30-32 cyclical strain,33 and hypoxia.34,35 In turn, the
Egr-1 transcription factor may induce the expression of a wide range of
target genes including PDGF-A,36 PDGF-B, tissue factor
(TF),27 Flt-1,37 transforming growth factor
(TGF)- We were interested in determining whether thrombin signaling in
endothelial cells resulted in increased expression of Egr-1. In the
present study, we show that thrombin induces Egr-1 protein and mRNA
levels in primary human endothelial cells and that this effect is
mediated by the inducible binding of the serum response factor (SRF) to
the most proximal of the 5 serum response elements (SREs), namely
SRE-1. These data suggest that SRF and Egr-1 be added to the growing
list of thrombin-responsive transcription factors.
Materials
Plasmid construction
Cell culture Human pulmonary artery endothelial cells (HPAECs), human coronary artery endothelial cells (HCAECs), and human umbilical vein endothelial cells (HUVECs) (all are from Clonetics, San Diego, CA) were grown in endothelial growth medium-2-MV (EGM-2-MV; Clonetics) to 95% confluence, serum-starved overnight in endothelial basal medium (EBM)-2 medium containing 0.5% fetal bovine serum (FBS), and incubated in the absence or presence of thrombin at the doses and for the times indicated. In inhibition studies, serum-starved endothelial cells were preincubated with 20 µM PD98059, 1.5 U/mL-5 U/mL hirudin, 5 µM BIM, 10 µM LY294002, or 3 µM SB203580 for 10 minutes and then treated with thrombin for the times indicated.RNA isolation and ribonuclease (RNase) protection assays HCAECs or HPAECs were grown in 6-well plates, serum-starved overnight in EBM-2 medium containing 0.5% FBS, and treated with or without thrombin in the presence or absence of inhibitors, as described above. Cells were harvested for RNA by adding RNA-STAT reagent (TEL-TEST, Friendwood, TX) directly into the wells. Total RNA was extracted according to the manufacturer's instructions. For RNase protection assays, a 334-bp human Egr-1 RT-PCR product was subcloned into the pPCR-Script Amp SK(+) cloning vector using PCR-Script AMP Cloning Kit (Stratagene). The Egr-1 cDNA insert was verified by automated sequencing. The cDNA plasmid template for -actin was
purchased from Ambion (Austin, TX).  -[32P] UTP-labeled
riboprobes were synthesized from the Egr-1 and -actin cDNA
templates, using T3 RNA polymerase (Ambion) and subsequently gel
purified. RNase protection assays were carried out using the RPA III
kit (Ambion). Briefly, the 2 riboprobes were mixed with 5 µg total
cellular RNA in a volume of 10 µL and hybridized at 42°C overnight
in hybridization buffer. The unhybridized RNAs were digested at 37°C
for 30 minutes with RNase A/RNase T1 mix. The protected fragments were
precipitated by adding the RNase Inactivation/Precipitation III
solution and separated on a 4% acrylamide/8M urea gel. The gels were
dried and autoradiographed. The intensity of the bands was analyzed by
the National Institutes of Health (NIH) Image software. Statistical
analyses were carried out using the Student t test.
Western blot analysis of Egr-1 protein expression To prepare whole-cell protein extracts, cells were washed twice with ice-cold phosphate buffered saline (PBS), harvested with a cell scraper, and lysed in ice-cold lysis buffer containing 20 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), pH7.5, 150 mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulfate (SDS), 1 mM EDTA (ethylenediaminetetraacetic acid), 1 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 1X protease inhibitor cocktail (Boehringer Mannheim, Mannheim, Germany) for 1 hour. The resulting lysates were centrifuged at 10 000g for 20 minutes, and the supernatants were saved as whole-cell protein extracts. Twenty micrograms of protein was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred to nitrocellulose membranes. Membranes were blocked with 2% nonfat dry milk in Tris (tris(hydroxymethyl)aminomethane)-buffered saline with 0.1% Tween 20 for 1 hour at room temperature. The blot was incubated with primary rabbit polyclonal anti-Egr-1 IgG (1:500 dilution) at room temperature for 1 hour, followed by secondary antibody goat-anti-rabbit horseradish peroxidase conjugate (1:1000 dilution) (Pierce, Rockford, IL). The blot was washed extensively between each incubation step. Peroxidase activity was visualized with an enhanced chemiluminescense substrate system (Amersham, Piscataway, NJ). The blots were subsequently stripped and reprobed with anti--actin antibody.
Transfections and analysis of luciferase activity HPAECs, HCAECs, and HUVECs were transfected using FuGENE 6 reagent as instructed by the manufacturer. 1 × 105 cells/well were seeded in 12-well plates 18 to 24 hours before transfection. A total of 0.5 µg of the reporter gene construct and 50 ng of a control plasmid containing the Renilla luciferase reporter gene under the control of a cytomegalovirus (CMV) enhancer/promoter (pRL-CMV; Promega, Madison, WI) was incubated with 2 µL FuGENE 6. After a 24-hour incubation with the transfection mix, cells were washed with PBS, serum-starved in EBM-2 medium containing 0.5% FBS for 18 hours, and treated in the absence or presence of thrombin and inhibitors for 6 hours. The cells were then lysed and assayed for luciferase activity using the Dual-luciferase reporter assay system (Promega). Light activity was measured in a luminometer (Lumat LB 9507; EG & G Berthold, Germany). All experiments were carried out in triplicate and repeated at least 4 times.Nuclear extracts and electrophoretic mobility shift assays Nuclear extracts were prepared by a modified Dignam procedure.42 Briefly, HPAECs were harvested by trypsinization, washed in ice-cold PBS, resuspended in one packed-cell volume of buffer A containing 10 mM HEPES (pH 7.9), 1.5 mM MgCl, 10 mM KCl, 50 mM NaF, 2 mM NaVO4, and 0.5 mM DTT and allowed to swell on ice for 15 minutes. The cells were lysed through a narrow-gauge hypodermic needle, and the cell homogenate was centrifuged at 12 000g for 20 seconds. The crude nuclear pellet was resuspended in 2/3 packed-cell volume of buffer C containing 20 mM HEPES, 25% vol/vol glycerol, 0.42 mM NaCl, 1.5 mM MgCl, 0.2 mM EDTA, 50 mM NaF, 2 mM NaVO4, 0.5 mM PMSF, and 0.5 mM DTT and incubated on ice for 30 minutes. The nuclear debris was pelleted by spinning for 5 minutes, and the supernatant dialyzed against buffer D containing 20 mM HEPES, 25% vol/vol glycerol, 0.1 M KCl, 0.2 mM EDTA, 50 mM NaF, 2 mM NaVO4, 0.5 mM PMSF, and 0.5 mM DTT. The oligonucleotides used for electrophoretic mobility shift assays are as follows: SRE-1 forward: 5'-TGCTTCCCATATATGGCCATGTA-3', SRE-1 reverse: 5'-TACATGGCCATATATGGGAAGCA-3', SRE-1 forward mutant: 5'-TGCTTCCCATAAGTGGCCATGTA-3' (TA mutated to AG), SRE-1 reverse mutant: 5'-TACATGGCCACTTATGGGAAGCA-3' (TA mutated to CT), TTCC forward mutant: 5'-TGCAACCCATATATGGCCATGTA-3' (TT mutated to AA), TTCC reverse mutant: 5'-TACATGGCCATATATGGGTTGCA-3' (AA mutated to TT), Ets consensus forward: 5'-GTGCCGGGGTAGGAAGTGGGCTGGG-3', and Ets consensus reverse: 5'-CCCAGCCCACTTCCTACCCCGGCAC-3'. Ten picomoles of double-stranded oligonucleotides was end-labeled with -32P-adenosine
triphosphate (ATP) and purified by G-50 spin columns (Amersham
Pharmacia). Five micrograms of nuclear extracts was mixed with 1 µg
of poly (dI-dC), 2 µL of 5X binding buffer containing 50 mM Tris HCl
(pH 8.0), 750 mM KCl, 2.5 mM EDTA, 0.5% Triton-X100, 62.5% vol/vol
glycerol, 1 mM DTT, and with 50 000 cpm radiolabeled probes with or
without unlabeled competitor probes. For supershift assays, nuclear
extracts were preincubated with antibodies against either SRF,
phospho-SRF, Elk-1, p-Elk-1, SAP-1a, Ets-1, or Ets-2 for 30 minutes at
room temperature before binding to the labeled probes. DNA-protein
complexes were resolved on a 5% nondenaturing polyacrylamide gel
containing 5% glycerol in 0.5X TBE (50 mM Tris, 50 mM boric acid, and
1 mM EDTA). The gels were dried and autoradiographed. Electrophoretic
mobility shift assays were carried out in triplicate, using independent
preparations of nuclear extracts. The signals were quantified with NIH
Image software, and statistical analyses were carried out using the
Student t test.
Immunolocalization studies Cells were grown to confluence on a glass coverslip, serum-starved overnight, and treated in the absence or presence of 1.5 U/mL thrombin for the times indicated. After removal of culture medium, the cells were washed with PBS and then fixed with ice-cold methanol. After extensive washing in PBS, the cells were incubated with a blocking buffer containing 0.4% bovine serum albumin (BSA) and 0.1% saponin for 10 minutes, followed by primary antibody against human SRF 1:100 for 1 hour at room temperature. Following extensive washes in PBS, the cells were incubated with a fluorescein isothiocyanate (FITC)-conjugated goat-anti-rabbit secondary antibody (1:200 dilution) for 1 hour. The slides were washed in PBS, mounted in 4',6-diamidino-2'-phenylindole dihydrochloride (DAPI)-containing Vectashield (Vector Laboratories, Burlingame, CA), and examined by fluorescence microscopy.
Thrombin induces Egr-1 expression in primary human endothelial cells To determine the effect of thrombin on Egr-1 mRNA levels, early passage HPAECs were serum-starved in 0.5% FBS overnight and incubated in the absence or presence of 1.5 U/mL thrombin for 1 hour. As shown in Figure 1A, the addition of thrombin resulted in a 6-fold induction of Egr-1 mRNA, an effect that was mimicked by 10 ng/mL TRAP, a 14-amino acid peptide representing the new amino terminus of PAR-1 after thrombin cleavage. Preincubation with the thrombin protease inhibitor, hirudin, resulted in a dose-dependent inhibition of thrombin's effect on Egr-1 expression (Figure 1A). Thrombin-mediated induction of Egr-1 was both time- and dose-dependent in HPAECs and HCAECs (Figure 1B,C shows HPAECs). In general, Egr-1 mRNA induction was maximal at 30 minutes of treatment with 0.5 U/mL thrombin. Finally, in Western blot analyses, thrombin was shown to increase Egr-1 protein levels, with maximal levels occurring between 30 minutes and 1 hour (Figure 2). Taken together, these results indicate that thrombin induces Egr-1 mRNA and protein levels in primary human endothelial cells.
Thrombin induces Egr-1 promoter activity in primary human endothelial cells We next tested whether the Egr-1 promoter contained information for thrombin response. HCAECs, HPAECs, and HUVECs were transiently transfected with the 1200-bp Egr-1 promoter construct (Egr-1-Luc), serum-starved for 18 hours, incubated in the absence or presence of thrombin for 6 hours, and harvested for luciferase activity. Egr-1 promoter activity was induced in all 3 cell types by 2.5- to 3-fold (Figure 3A). Since the transfection efficiency was greater in HUVECs compared with HPAECs or HCAECs, HUVECs were used in subsequent experiments. To delineate the promoter regions responsible for mediating the Egr-1 response to thrombin, a series of 5' and internal deletion mutants of the Egr-1 promoter were transiently transfected into HUVECs (Figure 3B). Deletion of the upstream AP-1 binding sites (Egr-1-C) had no effect on thrombin induction. The deletion of regions containing the 3' SRE cluster abolished thrombin response (Egr-1-B, Egr-1-D, and Egr-1-G), whereas the isolated deletion of 5' SRE cluster had no such effect (Egr-1 E). When coupled to a heterologous core promoter, the region spanning the 5' SRE cluster ( 425 to 250) did not confer thrombin response (Figure 3C). In contrast, the fragment containing the 3' SRE cluster (125 to 70) alone or in combination with the 5' SRE cluster was
induced 2.4-fold by thrombin (Figure 3C). These data indicate that the
region between 125 and 70 of the Egr-1 promoter contains information for thrombin response. To determine whether SRE-1 and/or
SRE-2 was responsible for transducing the thrombin signal, we generated
a series of SRE mutants and tested the resulting promoter-reporter gene
constructs for thrombin response in transient transfection assays. As
shown in Figure 4, constructs containing point mutations of all 5 SREs (mSRE1,2,3,4,5), the 2 proximal SREs (mSRE1,2), or SRE-1 alone (mSRE1)
did not respond to thrombin treatment. A point mutation of SRE-2
(mSRE2) resulted in a slight decrease in thrombin response,
whereas a mutation of the 5' SRE cluster (mSRE3,4,5) had no
effect on thrombin stimulation. Taken together, these findings strongly
implicate SRE-1 as the thrombin-responsive element of the
Egr-1 promoter. The 3' SRE cluster has been shown to contain
a single Ets motif at position 93, relative to the start site of
transcription.43 To test whether this site was necessary
for mediating the thrombin response, a mutation was introduced into the
Ets motif, and the resulting plasmid was transfected into HUVECs. As
shown in Figure 4, this construct retained thrombin responsiveness,
suggesting that the proximal Ets site is not necessary for transducing
the thrombin signal.
Thrombin induces the binding of SRF to SRE-1 Next, we used electrophoretic mobility shift assays to determine the effect of thrombin on DNA-protein interactions. Since SRE-1, but not the proximal Ets motif, was necessary for mediating the thrombin response in transient transfection assays, we focused on the SRE-1 sequence alone (Figure 5A, SRE-1 probe). As shown in Figure 5B, incubation of the probe with nuclear extracts from untreated and thrombin-treated HPAECs resulted in specific a DNA-protein complex (closed arrow, Figure 5B, lanes 1 and 13). The DNA-protein complex was inhibited by the addition of a 100-fold molar excess of unlabeled cold-competitor (Figure 5B, lanes 2 and 14), but not by the same concentration of unlabeled mutant SRE-1 (Figure 5B, lanes 3 and 15) or unlabeled consensus Ets probe (derived from the human Flt-1 promoter; Figure 5B, lanes 12 and 24). Of note, the SRE-1 site contains a potential overlapping Ets binding domain (TTCC; Figure 5A). However, the addition of 100-fold molar excess of unlabeled cold-competitor containing a mutation of the TTCC sequence (Figure 5B, lanes 4 and 16) resulted in a complete loss of DNA-protein complexes, arguing against the presence of a specific Ets DNA-protein complex.
The faster-migrating DNA-protein complexes were nonspecific (open arrows), as they were inhibited by the addition of wild-type and mutant self-competitors as well as competitor sequence from an unrelated gene (consensus Ets probe from the Flt-1 promoter). To determine the identity of the protein in the specific DNA-protein complex, the binding reactions were incubated with antibodies to SRF, phospho-SRF, Elk-1, p-Elk-1, SAP-1a, Ets-1, and Ets-2. Preincubation with antibodies to SRF (Figure 5B, lanes 5 and 17) and phospho-SRF (Figure 5B, lanes 6 and 18) resulted in a supershift of the specific DNA-protein complex (Figure 5B, asterisk), whereas the addition of IgG control (not shown) or antibodies against Elk-1 (Figure 5B, lanes 7 and 19), p-Elk-1 (Figure 5B, lanes 8 and 20), SAP-1a (Figure 5B, lanes 9 and 21), Ets-1 (Figure 5B, lanes 10 and 22), or Ets-2 (Figure 5B, lanes 11 and 23) did not produce any change in mobility. Nuclear extracts from thrombin-treated endothelial cells displayed increased levels of total SRF binding (1.93 ± 0.17-fold, P < .05; Figure 5B, compare lanes 1 and 5 with lanes 13 and 17, respectively). Previous studies have shown that the inducible phosphorylation of SRF results in increased DNA binding avidity. To determine whether thrombin induces the binding of phosphorylated SRF to SRE-1, we carried out supershift assays with an anti-phospho-SRF antibody. The addition of this antibody resulted in a stronger supershift of the SRE-SRF complex in thrombin treated cells compared with untreated controls (1.94 ± 0.19-fold, P < .05; Figure 5B, compare lanes 6 and 18). Taken together, the data suggest that thrombin induces the binding of both total and phosphorylated SRF to SRE-1. Thrombin-mediated induction of the Egr-1 gene and promoter is mediated by a MEK1/2-dependent MAPK pathway To delineate the signaling pathway involved in mediating the thrombin response, we carried out RNase protection assays of Egr-1 mRNA from untreated and thrombin-treated HPAECs preincubated in the absence or presence of chemical inhibitors of mitogen-activated protein kinase (MAPK), protein kinase C (PKC), and phosphatidylinositol 3-kinase (PI3K). Thrombin-mediated induction of Egr-1 expression was blocked by pretreatment with the MAPK kinase (MEK) inhibitor PD98059 (Figure 6, PD), but not by the p38 MAPK inhibitor SB203580 (Figure 6, SB), the PKC inhibitor BIM (Figure 6, BIM), or the PI3K inhibitor LY294002 (Figure 6, LY). Similarly, in transient transfection assays, thrombin-mediated induction of the full-length Egr-1 promoter was abrogated by pretreatment with PD98059, but not with SB203580, BIM, or LY294002 (Figure 7). These findings suggest that thrombin stimulation of the endogenous Egr-1 gene and the Egr-1 promoter is mediated by an ERK1/2 MAPK-dependent, p38/PKC/PI3K-independent pathway.
Thrombin induces the nuclear translocation of SRF In the last set of experiments, we used immunofluorescent studies to study the effect of thrombin on SRF localization in HPAECs. Thrombin treatment for 5 to 120 minutes resulted in the nuclear translocation of SRF, with maximal levels occurring at 30 minutes (Figure 8 shows 5 minutes and 30 minutes). Together with our previous results, these data suggest that thrombin induces the nuclear translocation of SRF and that this effect is coupled to the transactivation of the Egr-1 promoter.
The coagulation and inflammatory pathways are tightly linked. Inflammatory mediators induce the expression of tissue factor on circulating monocytes, thereby contributing to the initiation of coagulation. Moreover, cytokines and other inflammatory mediators activate endothelial cells, resulting in a local alteration of the hemostatic balance.44,45 Thrombin, once generated, may further activate endothelial cells and amplify the proinflammatory response. Until recently, little was known about the mechanisms by which thrombin
induces gene expression. Thrombin has subsequently been shown to
stimulate PDGF-B chain expression via the inducible binding of a Y-box
protein to a CCACCC consensus sequence in the upstream promoter
region.46,47 A similar mechanism was proposed for the
thrombin response of the endothelial protein C receptor.48 Thrombin-mediated induction of ICAM-1 was demonstrated to involve the
binding of p65 homodimers to a single NF- The murine and human Egr-1 promoters contain 5 functional SREs, organized into 2 clusters: a 5' cluster of 3 SREs and a 3' cluster of 2 SREs. Collectively, the 5 SREs are responsible for transducing most, if not all, signals that activate Egr-1 expression. The 5' SRE cluster has been shown to mediate the response to the majority of extracellular signals, including EGF,28 shear stress,30 growth hormone,51 urea,41 hypotonicity, lipopolysaccharide (LPS),52 granulocyte colony-stimulating factor (G-CSF),53 and hypoxia.35 In nonendothelial cells, the 3' cluster has been implicated in the response to glucose-induced depolarization54 and granulocyte-macrophage colony-stimulating factor (GM-CSF).55,56 To our knowledge, the present study is the first to uncover a role for the most proximal SRE (SRE-1) in mediating inducible Egr-1 expression in primary endothelial cells. The SRE is an important converging point for signal transduction cascades. The SRF is a ubiquitous 67-kDa nuclear transcription factor that acts by binding to the SRE consensus site, CC(A/T)6GG. The prototypic SRE binds to a ternary complex that includes a homodimer of SRF and member of the ternary complex factors, including Elk-1, SAP-1, and SAP-2/ERP/Net. Previous studies have shown that the response of the 5' cluster of SREs to extracellular signals is mediated by the coordinate action of SRF and ternary complex factor (TCF).30,35,51,52 In contrast, our results suggest that SRE-1 transduces the thrombin signal by an SRF-dependent, TCF-independent mechanism. For example, the mutation of SRE-1, but not the proximal Ets motif, resulted in a loss of thrombin responsiveness. Moreover, in electrophoretic mobility shift assays, thrombin resulted in the inducible binding of SRF and phospho-SRF to SRE-1 in the absence of TCF. Consistent with our findings, a previous study of preadipocyte cells
reported that SRE-1 is constitutively bound by SRF but not by
TCF.51 Thrombin receptor activation in NIH3T3 cells
resulted in an SRF-dependent, TCF-independent transactivation of the
c-fos SRE.57 In pancreatic islet Previous investigations have shown that phosphorylation of SRF at Ser-103 results in increased DNA binding and enhanced transcriptional activity.59,60 Several signaling pathways have been implicated in this process, including ERK1/2-dependent MAPKAP-K1,60 p38-dependent MAPKAP-K2,61 and CaM kinases.58 We demonstrated that thrombin induces the binding of phospho-SRF to SRE-1, suggesting that thrombin's actions may be mediated by the inducible phosphorylation of the transcription factor. Another possible mechanism by which thrombin mediates SRE-dependent induction of the Egr-1 gene is through the nuclear translocation of SRF, an effect that may be regulated independently of Ser-103 phosphorylation.62 The observation that thrombin induces the translocation of SRF from the cytoplasm to the nucleus is consistent with the previously reported effects of serum on the subcellular distribution of SRF.63 We have shown that thrombin-mediated induction of Egr-1 is dependent on
MEK/ERK, but not p38 MAPK, PKC, or PI3K. Previous studies have
established an important role for MEK/ERK in mediating Egr-1 response
to other mediators, including LPS, growth factors, hormones, and
TNF- There is a growing appreciation that thrombin signaling contributes to
a proinflammatory state. Egr-1 has been reported to induce a number of
downstream genes, including TF, TNF-
Submitted February 8, 2002; accepted June 18, 2002.
Prepublished online as Blood First Edition Paper, June 28, 2002; DOI 10.1182/blood-2002-02-0415.
Supported by the National Institute of Health grant HL 65216-03.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: William C. Aird, Beth Israel Deaconess Medical Center, Molecular Medicine, RW-663, 330 Brookline Ave, Boston, MA 02215; e-mail: waird{at}caregroup.harvard.edu.
1. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1057;199:64-1068. 2. Gerszten RE, Chen J, Ishii M, et al. Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. Nature. 1994;368:648-651[CrossRef][Medline] [Order article via Infotrieve].
3.
Lorant DE, Patel KD, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA.
Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils.
J Cell Biol.
1991;115:223-234
4.
Zimmerman GA, McIntyre TM, Prescott SM.
Production of platelet-activating factor by human vascular endothelial cells: evidence for a requirement for specific agonists and modulation by prostacyclin.
Circulation.
1985;72:718-727
5.
Ellis CA, Malik AB, Gilchrist A, et al.
Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of Gi-linked Ras/mitogen-activated protein kinase pathway.
J Biol Chem.
1999;274:13718-13727
6.
Tsopanoglou NE, Maragoudakis ME.
On the mechanism of thrombin-induced angiogenesis: potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors.
J Biol Chem.
1999;274:23969-23976
7.
Shankar R, de la Motte CA, Poptic EJ, DiCorleto PE.
Thrombin receptor-activating peptides differentially stimulate platelet-derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells.
J Biol Chem.
1994;269:13936-13941
8.
Lidington EA, Haskard DO, Mason JC.
Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury.
Blood.
2000;96:2784-2792 9. Golden CL, Nick HS, Visner GA. Thrombin regulation of endothelin-1 gene in isolated human pulmonary endothelial cells. Am J Physiol. 1998;274:L854-L863[Medline] [Order article via Infotrieve]. 10. Kaplanski G, Fabrigoule M, Boulay V, et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression. J Immunol. 1997;158:5435-5441[Abstract]. 11. Colotta F, Sciacca FL, Sironi M, Luini W, Rabiet MJ, Mantovani A. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol. 1994;144:975-985[Abstract].
12.
Kaplanski G, Marin V, Fabrigoule M, et al.
Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106).
Blood.
1998;92:1259-1267
13.
Rahman A, Anwar KN, True AL, Malik AB.
Thrombin-induced p65 homodimer binding to downstream NF-kappa B site of the promoter mediates endothelial ICAM-1 expression and neutrophil adhesion.
J Immunol.
1999;162:5466-5476
14.
van Nieuw Amerongen GP, van Delft S, Vermeer MA, Collard JG, van Hinsbergh VW.
Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho kinase and protein tyrosine kinases.
Circ Res.
2000;87:335-340 15. Malik AB, Fenton JW 2nd. Thrombin-mediated increase in vascular endothelial permeability. Semin Thromb Hemost. 1992;18:193-199[Medline] [Order article via Infotrieve].
16.
Olivot JM, Estebanell E, Lafay M, Brohard B, Aiach M, Rendu F.
Thrombomodulin prolongs thrombin-induced extracellular signal-regulated kinase phosphorylation and nuclear retention in endothelial cells.
Circ Res.
2001;88:681-687 17. Zimmerman GA, McIntyre TM, Prescott SM. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro. J Clin Invest. 1985;76:2235-2246[Medline] [Order article via Infotrieve].
18.
Christy BA, Lau LF, Nathans D.
A gene activated in mouse 3T3 cells by serum growth factors encodes a protein with "zinc finger" sequences.
Proc Natl Acad Sci U S A.
1988;85:7857-7861 19. Gashler A, Sukhatme VP. Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol. 1995;50:191-224[Medline] [Order article via Infotrieve].
20.
Lemaire P, Revelant O, Bravo R, Charnay P.
Two mouse genes encoding potential transcription factors with identical DNA-binding domains are activated by growth factors in cultured cells.
Proc Natl Acad Sci U S A.
1988;85:4691-4695
21.
Milbrandt J.
A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor.
Science.
1987;238:797-799 22. Sukhatme VP, Cao XM, Chang LC, et al. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell. 1988;53:37-43[CrossRef][Medline] [Order article via Infotrieve]. 23. Waters CM, Hancock DC, Evan GI. Identification and characterisation of the egr-1 gene product as an inducible, short-lived, nuclear phosphoprotein. Oncogene. 1990;5:669-674[Medline] [Order article via Infotrieve].
24.
Delbridge GJ, Khachigian LM.
FGF-1-induced platelet-derived growth factor-A chain gene expression in endothelial cells involves transcriptional activation by early growth response factor-1.
Circ Res.
1997;81:282-288 25. Ko Y, Totzke G, Schiermeyer B, et al. Reverse transcriptase-polymerase chain reaction (RT-PCR): a sensitive method to examine basic fibroblast growth factor-induced expression of the early growth response gene-1 (egr-1) in human umbilical arterial endothelial cells. Mol Cell Probes. 1995;9:215-222[CrossRef][Medline] [Order article via Infotrieve].
26.
Santiago FS, Lowe HC, Day FL, Chesterman CN, Khachigian LM.
Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2.
Am J Pathol.
1999;154:937-944
27.
Mechtcheriakova D, Wlachos A, Holzmuller H, Binder BR, Hofer E.
Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1.
Blood.
1999;93:3811-3823
28.
Tsai JC, Liu L, Guan J, Aird WC.
The Egr-1 gene is induced by epidermal growth factor in ECV304 cells and primary endothelial cells.
Am J Physiol Cell Physiol.
2000;279:C1414-C1424
29.
Liu L, Tsai JC, Aird WC.
Egr-1 gene is induced by the systemic administration of the vascular endothelial growth factor and the epidermal growth factor.
Blood.
2000;96:1772-1781 30. Schwachtgen JL, Houston P, Campbell C, Sukhatme V, Braddock M. Fluid shear stress activation of egr-1 transcription in cultured human endothelial and epithelial cells is mediated via the extracellular signal-related kinase 1/2 mitogen-activated protein kinase pathway. J Clin Invest. 1998;101:2540-2549[Medline] [Order article via Infotrieve].
31.
Chiu JJ, Wung BS, Hsieh HJ, Lo LW, Wang DL.
Nitric oxide regulates shear stress-induced early growth response-1: expression via the extracellular signal-regulated kinase pathway in endothelial cells.
Circ Res.
1999;85:238-246
32.
Houston P, Dickson MC, Ludbrook V, et al.
Fluid shear stress induction of the tissue factor promoter in vitro and in vivo is mediated by Egr-1.
Arterioscler Thromb Vasc Biol.
1999;19:281-289
33.
Wung BS, Cheng JJ, Chao YJ, Hsieh HJ, Wang DL.
Modulation of Ras/Raf/extracellular signal-regulated kinase pathway by reactive oxygen species is involved in cyclic strain-induced early growth response-1 gene expression in endothelial cells.
Circ Res.
1999;84:804-812 34. Lo LW, Cheng JJ, Chiu JJ, Wung BS, Liu YC, Wang DL. Endothelial exposure to hypoxia induces Egr-1 expression involving PKCalpha-mediated Ras/Raf-1/ERK1/2 pathway. J Cell Physiol. 2001;188:304-312[CrossRef][Medline] [Order article via Infotrieve].
35.
Yan SF, Lu J, Zou YS, et al.
Hypoxia-associated induction of early growth response-1 gene expression.
J Biol Chem.
1999;274:15030-15040
36.
Khachigian LM, Williams AJ, Collins T.
Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells.
J Biol Chem.
1995;270:27679-27686
37.
Vidal F, Aragones J, Alfranca A, de Landazuri MO.
Up-regulation of vascular endothelial growth factor receptor Flt-1 after endothelial denudation: role of transcription factor Egr-1.
Blood.
2000;95:3387-3395
38.
Haas TL, Stitelman D, Davis SJ, Apte SS, Madri JA.
Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium.
J Biol Chem.
1999;274:22679-22685 39. Khachigian LM, Lindner V, Williams AJ, Collins T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science. 1996;271:1427-1431[Abstract]. 40. McCaffrey TA, Fu C, Du B, et al. High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis. J Clin Invest. 2000;105:653-662[Medline] [Order article via Infotrieve].
41.
Cohen DM, Gullans SR, Chin WW.
Urea inducibility of egr-1 in murine inner medullary collecting duct cells is mediated by the serum response element and adjacent Ets motifs.
J Biol Chem.
1996;271:12903-12908 42. Dignam JD, Martin PL, Shastry BS, Roeder RG. Eukaryotic gene transcription with purified components. Methods Enzymol. 1983;101:582-598[Medline] [Order article via Infotrieve]. 43. Watson DK, Robinson L, Hodge DR, Kola I, Papas TS, Seth A. FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements. Oncogene. 1997;14:213-221[CrossRef][Medline] [Order article via Infotrieve]. 44. Gross PL, Aird WC. The endothelium and thrombosis. Semin Thromb Hemost. 2000;26:463-478[CrossRef][Medline] [Order article via Infotrieve]. 45. Aird WC. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med. 2001;29:S28-S35[CrossRef][Medline] [Order article via Infotrieve].
46.
Scarpati EM, DiCorleto PE.
Identification of a thrombin response element in the human platelet- derived growth factor B-chain (c-sis) promoter.
J Biol Chem.
1996;271:3025-3032
47.
Stenina OI, Shaneyfelt KM, DiCorleto PE.
Thrombin induces the release of the Y-box protein dbpB from mRNA: a mechanism of transcriptional activation.
Proc Natl Acad Sci U S A.
2001;98:7277-7282
48.
Gu JM, Fukudome K, Esmon CT.
Characterization and regulation of the 5'-flanking region of the murine endothelial protein C receptor gene.
J Biol Chem.
2000;275:12481-12488
49.
Minami T, Aird WC.
Thrombin stimulation of the vascular cell adhesion molecule-1 promoter in endothelial cells is mediated by tandem nuclear factor-kappa B and GATA motifs.
J Biol Chem.
2001;276:47632-47641
50.
Li QJ, Vaingankar S, Sladek FM, Martins-Green M.
Novel nuclear target for thrombin: activation of the Elk1 transcription factor leads to chemokine gene expression.
Blood.
2000;96:3696-3706
51.
Clarkson RW, Shang CA, Levitt LK, Howard T, Waters MJ.
Ternary complex factors Elk-1 and Sap-1a mediate growth hormone-induced transcription of egr-1 (early growth response factor-1) in 3T3-F442A preadipocytes.
Mol Endocrinol.
1999;13:619-631
52.
Guha M, O'Connell MA, Pawlinski R, et al.
Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression.
Blood.
2001;98:1429-1439
53.
Mora-Garcia P, Sakamoto KM.
Granulocyte colony-stimulating factor induces Egr-1 up-regulation through interaction of serum response element-binding proteins.
J Biol Chem.
2000;275:22418-22426
54.
Bernal-Mizrachi E, Wice B, Inoue H, Permutt MA.
Activation of serum response factor in the depolarization induction of Egr-1 transcription in pancreatic islet beta-cells.
J Biol Chem.
2000;275:25681-25689
55.
Sakamoto KM, Fraser JK, Lee HJ, Lehman E, Gasson JC.
Granulocyte-macrophage colony-stimulating factor and interleukin-3 signaling pathways converge on the CREB-binding site in the human egr-1 promoter.
Mol Cell Biol.
1994;14:5975-5985
56.
Watanabe S, Kubota H, Sakamoto KM, Arai K.
Characterization of cis-acting sequences and trans-acting signals regulating early growth response 1 and c-fos promoters through the granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells.
Blood.
1997;89:1197-1206
57.
Mao J, Yuan H, Xie W, Simon MI, Wu D.
Specific involvement of G proteins in regulation of serum response factor-mediated gene transcription by different receptors.
J Biol Chem.
1998;273:27118-27123 58. Miranti CK, Ginty DD, Huang G, Chatila T, Greenberg ME. Calcium activates serum response factor-dependent transcription by a Ras- and Elk-1-independent mechanism that involves a Ca2+/calmodulin-dependent kinase. Mol Cell Biol. 1995;15:3672-3684[Abstract]. 59. Janknecht R, Hipskind RA, Houthaeve T, Nordheim A, Stunnenberg HG. Identification of multiple SRF N-terminal phosphorylation sites affecting DNA binding properties. Embo J. 1992;11:1045-1054[Medline] [Order article via Infotrieve].
60.
Rivera VM, Miranti CK, Misra RP, et al.
A growth factor-induced kinase phosphorylates the serum response factor at a site that regulates its DNA-binding activity.
Mol Cell Biol.
1993;13:6260-6273
61.
Heidenreich O, Neininger A, Schratt G, et al.
MAPKAP kinase 2 phosphorylates serum response factor in vitro and in vivo.
J Biol Chem.
1999;274:14434-14443 62. Gauthier-Rouviere C, Vandromme M, Lautredou N, et al. The serum response factor nuclear localization signal: general implications for cyclic AMP-dependent protein kinase activity in control of nuclear translocation. Mol Cell Biol. 1995;15:433-444[Abstract].
63.
Camoretti-Mercado B, Liu HW, Halayko AJ, et al.
Physiological control of smooth muscle-specific gene expression through regulated nuclear translocation of serum response factor.
J Biol Chem.
2000;275:30387-30393
64.
Mechtcheriakova D, Schabbauer G, Lucerna M, et al.
Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells.
Faseb J.
2001;15:230-242
65.
Hodge C, Liao J, Stofega M, Guan K, Carter-Su C, Schwartz J.
Growth hormone stimulates phosphorylation and activation of elk-1 and expression of c-fos, egr-1, and junB through activation of extracellular signal-regulated kinases 1 and 2.
J Biol Chem.
1998;273:31327-31336 66. Poser S, Impey S, Trinh K, Xia Z, Storm DR. SRF-dependent gene expression is required for PI3-kinase-regulated cell proliferation. Embo J. 2000;19:4955-4966[CrossRef][Medline] [Order article via Infotrieve].
67.
Wakiya K, Begue A, Stehelin D, Shibuya M.
A cAMP response element and an Ets motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth factor receptor 1) gene.
J Biol Chem.
1996;271:30823-30828
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. Flanagin, J. D. Nelson, D. G. Castner, O. Denisenko, and K. Bomsztyk Microplate-based chromatin immunoprecipitation method, Matrix ChIP: a platform to study signaling of complex genomic events Nucleic Acids Res., February 11, 2008; 36(3): e17 - e17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Kinney, U. M. Chandrasekharan, L. Mavrakis, and P. E. DiCorleto VEGF and thrombin induce MKP-1 through distinct signaling pathways: role for MKP-1 in endothelial cell migration Am J Physiol Cell Physiol, January 1, 2008; 294(1): C241 - C250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. O'Brien, M. A. Richardson, S. F. Mehrbod, D. T. Berg, B. Gerlitz, A. Gupta, and B. W. Grinnell Activated Protein C Decreases Tumor Necrosis Factor Related Apoptosis-Inducing Ligand by an EPCR- Independent Mechanism Involving Egr-1/Erk-1/2 Activation Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2634 - 2641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. U. Latasa, D. Couton, C. Charvet, A. Lafanechere, J.-E. Guidotti, Z. Li, D. Tuil, D. Daegelen, C. Mitchell, and H. Gilgenkrantz Delayed liver regeneration in mice lacking liver serum response factor Am J Physiol Gastrointest Liver Physiol, April 1, 2007; 292(4): G996 - G1001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Khachigian Early Growth Response-1 in Cardiovascular Pathobiology Circ. Res., February 3, 2006; 98(2): 186 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R.S. Day, K. M. Taylor, E. A. Lidington, J. C. Mason, D. O. Haskard, A. M. Randi, and R. C. Landis Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1 J. Thorac. Cardiovasc. Surg., January 1, 2006; 131(1): 21 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kamimura, C. Viedt, A. Dalpke, M. E. Rosenfeld, N. Mackman, D. M. Cohen, E. Blessing, M. Preusch, C. M. Weber, J. Kreuzer, et al. Interleukin-10 Suppresses Tissue Factor Expression in Lipopolysaccharide-Stimulated Macrophages via Inhibition of Egr-1 and a Serum Response Element/MEK-ERK1/2 Pathway Circ. Res., August 19, 2005; 97(4): 305 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-Q. Wu and W. C. Aird Thrombin, TNF-{alpha}, and LPS exert overlapping but nonidentical effects on gene expression in endothelial cells and vascular smooth muscle cells Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H873 - H885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. McLaughlin, M. R. Mazzoni, J. H. Cleator, L. Earls, A. L. Perdigoto, J. D. Brooks, J. A. S. Muldowney III, D. E. Vaughan, and H. E. Hamm Thrombin Modulates the Expression of a Set of Genes Including Thrombospondin-1 in Human Microvascular Endothelial Cells J. Biol. Chem., June 10, 2005; 280(23): 22172 - 22180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, K. Pelekanakis, and M. J. Woolkalis Thrombin and Tumor Necrosis Factor {alpha} Synergistically Stimulate Tissue Factor Expression in Human Endothelial Cells: REGULATION THROUGH c-Fos AND c-Jun J. Biol. Chem., August 20, 2004; 279(34): 36142 - 36147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Tullai, M. E. Schaffer, S. Mullenbrock, S. Kasif, and G. M. Cooper Identification of Transcription Factor Binding Sites Upstream of Human Genes Regulated by the Phosphatidylinositol 3-Kinase and MEK/ERK Signaling Pathways J. Biol. Chem., May 7, 2004; 279(19): 20167 - 20177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Minami, A. Sugiyama, S.-Q. Wu, R. Abid, T. Kodama, and W. C. Aird Thrombin and Phenotypic Modulation of the Endothelium Arterioscler. Thromb. Vasc. Biol., January 1, 2004; 24(1): 41 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Keeton, K. D. Bortoff, W. L. Bennett, J. L. Franklin, D. Y. Venable, and J. L. Messina Insulin-Regulated Expression of Egr-1 and Krox20: Dependence on ERK1/2 and Interaction with p38 and PI3-Kinase Pathways Endocrinology, December 1, 2003; 144(12): 5402 - 5410. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
GGGCTTaaTGC (mETS-1), CCATATATGG
B site in the upstream promoter region,